Kanagawa-ken, Japan

Megumi Imai


Average Co-Inventor Count = 12.6

ph-index = 3

Forward Citations = 26(Granted Patents)


Company Filing History:


Years Active: 1997-2000

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Megumi Imai: Innovator in Pharmacological Compounds

Introduction

Megumi Imai is a prominent inventor based in Kanagawa-ken, Japan. She has made significant contributions to the field of pharmacology, particularly through her innovative work on tricyclic benzazepine compounds. With a total of 3 patents, her research has paved the way for advancements in medicinal chemistry.

Latest Patents

Imai's latest patents include groundbreaking work on tricyclic benzazepine compounds and triazole intermediates. These compounds serve as intermediates for pharmacologically active tricyclic benzazepine and benzothiazepine derivatives. The specific formulae (II), (III), (IV), and (V) represent various configurations where R can denote hydrogen, alkyl, phenylalkyl, or a protective group of a triazole ring. Additionally, R¹-R⁵ can represent hydrogen, alkyl, alkenyl, alkoxy, amino, oxim, or hydroxyl, while R⁴¹ can represent hydrogen or C₁-₆ alkyl, which may be optionally substituted or a protective group for a carboxyl group.

Career Highlights

Throughout her career, Megumi Imai has worked with notable companies such as Meiji Seika Kabushiki Kaisha and Meiji Seika Kaisha, Ltd. Her expertise in pharmacological compounds has been instrumental in the development of new medicinal products.

Collaborations

Imai has collaborated with esteemed colleagues, including Yasuo Ohtsuka and Takashi Shishikura. These partnerships have further enhanced her research and innovation in the field.

Conclusion

Megumi Imai's contributions to pharmacology through her patents and collaborations highlight her as a key figure in the development of new medicinal compounds. Her work continues to influence the field and inspire future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…